These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 3604471)

  • 21. Maximal androgen blockade versus total androgen suppression.
    Dumez H; Van Poppel H; Baert L; Paridaens R
    Acta Urol Belg; 1997 Mar; 65(1):49-54. PubMed ID: 9175283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hormonal effects of cessation of estrogen treatment for prostatic carcinoma.
    Tomić R; Bergman B
    J Urol; 1987 Oct; 138(4):801-3. PubMed ID: 3116281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversibility of androgen deprivation therapy in patients with prostate cancer.
    Fridmans A; Chertin B; Koulikov D; Lindenberg T; Gelber H; Leiter C; Farkas A; Spitz IM
    J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Plasma testosterone: a sound criterion of the effectiveness of hormonal treatment of prostatic carcinoma].
    Maleeva A; Tsvetkov M; Kekhaĭova M
    Vutr Boles; 1980; 19(3):42-6. PubMed ID: 6771918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.
    Bogdanos J; Karamanolakis D; Milathianakis C; Repousis P; Tsintavis A; Koutsilieris M
    Anticancer Res; 2003; 23(2C):1757-62. PubMed ID: 12820454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Secondary endocrine therapy with oral estrogen for relapsed prostate cancer].
    Onita T; Igawa T; Hisamatsu H; Sakai H; Kanetake H
    Hinyokika Kiyo; 2009 Oct; 55(10):595-8. PubMed ID: 19926941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of radical prostatectomy on serum hormone levels.
    Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
    J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy.
    Nejat RJ; Rashid HH; Bagiella E; Katz AE; Benson MC
    J Urol; 2000 Dec; 164(6):1891-4. PubMed ID: 11061874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Hormonal treatment in cancer of the prostate].
    Boccon-Gibod L
    Rev Prat; 1987 Feb; 37(7):386-90. PubMed ID: 3823774
    [No Abstract]   [Full Text] [Related]  

  • 32. On the effects of oestrogen in the male. Some effects of different oestrogenic substances in rats and men with prostatic carcinoma.
    Daehlin L
    Scand J Urol Nephrol Suppl; 1985; 91():1-44. PubMed ID: 3868029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
    Shulman MJ; Karam JA; Benaim EA
    Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
    Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
    Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S; Lawrentschuk N; Grills RJ; Neerhut G
    J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absence of relationship between steroid hormone levels and prostate cancer tumor grade.
    Sher DJ; Mantzoros C; Jacobus S; Regan MM; Lee GS; Oh WK
    Urology; 2009 Feb; 73(2):356-61; discussion 361-2. PubMed ID: 19036418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polyestradiol phosphate and ethinyl estradiol in treatment of prostatic carcinoma.
    Lindstedt E
    Scand J Urol Nephrol Suppl; 1980; 55():95-7. PubMed ID: 6938044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron].
    Klebingat KJ; Panzig E; Lorenz G; Steinhauser I; Fiedler R
    Z Urol Nephrol; 1987 Mar; 80(3):139-47. PubMed ID: 3300097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
    Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
    J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes.
    Berg A; Dahl AA; Bruland ØS; Bjøro T; Aanensen MS; Fosså SD
    Prostate Cancer Prostatic Dis; 2009; 12(3):269-76. PubMed ID: 19290019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.